Relation of Change in Apolipoprotein B/Apolipoprotein A-I Ratio to Coronary Plaque Regression After Pravastatin Treatment in Patients With Coronary Artery Disease

American Journal of Cardiology

Volumn 105, Issue 2, 2010, Pages 144-148

  Tani, Shigemasa ^a,b   Nagao, Ken ^a,b   Anazawa, Takeo ^a,b   Kawamata, Hirofumi ^a,b   Furuya, Shingo ^a,b   Takahashi, Hiroshi ^a,b   Iida, Kiyoshi ^a,b   Matsumoto, Michiaki ^a,b   Washio, Takehiko ^a,b   Kumabe, Narimichi ^a,b   Hirayama, Atsushi ^b  

^a NIHON UNIVERSITY   (Japan)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN C2; APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOSORBIDE DINITRATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DRUG EFFECT; FEMALE; HUMAN; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REMISSION; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRAVASTATIN; PROSPECTIVE STUDIES; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 73149094119     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.08.670     Document Type: Article

References (24)

1. Walldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., and Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358 (2001) 2026-2033
2. Sniderman A.D., Furberg C.D., Keech A., Roeters van Lennep J.E., Frohlich J., Jungner I., and Walldius G. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361 (2003) 777-780
3. Kastelein J.J., van der Steeg W.A., Holme I., Gaffney M., Cater N.B., Barter P., Deedwania P., Olsson A.G., Boekholdt S.M., Demicco D.A., Szarek M., LaRosa J.C., Pedersen T.R., Grundy S.M., TNT Study Group, and IDEAL Study Group. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 117 (2008) 3002-3009
4. Walldius G., and Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy-a review of the evidence. J Intern Med 259 (2006) 493-519
5. McQueen M.J., Hawken S., Wang X., Ounpuu S., Sniderman A., Probstfield J., Steyn K., Sanderson J.E., Hasani M., Volkova E., Kazmi K., Yusuf S., and INTERHEART Study Investigators. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 372 (2008) 224-233
6. Smith S.C., Blair S.N., Bonow R.O., Brass L.M., Cerqueira M.D., Dracup K., Fuster V., Gotto A., Grundy S.M., Miller N.H., Jacobs A., Jones D., Krauss R.M., Mosca L., Ockene I., Pasternak R.C., Pearson T., Pfeffer M.A., Starke R.D., and Taubert K.A. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. J Am Coll Cardiol 38 (2001) 1581-1583
7. Teramoto T., Sasaki J., Ueshima H., Egusa G., Kinoshita M., Shimamoto K., Daida H., Biro S., Hirobe K., Funahashi T., Yokote K., and Yokode M. Treatment-therapeutic lifestyle modification. J Atheroscler Thromb 15 (2008) 109-115
8. Tani S., Nagao K., Anazawa T., Kawamata H., Iida K., Matsumoto M., Sato Y., and Hirayama A. Association of circulating leukocyte count with coronary atherosclerosis regression after pravastatin treatment. Atherosclerosis 198 (2008) 360-365
9. Junyent M., Zambón D., Gilabert R., Cofán M., Núñez I., and Ros E. Carotid atherosclerosis in familial combined hyperlipidemia associated with the APOB/APOA-I ratio. Atherosclerosis 197 (2008) 740-746
10. Schmidt C., and Fagerberg B. ApoB/apoAI ratio is related to femoral artery plaques in 64-year-old women also in cases with low LDL cholesterol. Atherosclerosis 196 (2008) 817-822
11. Nicholls S.J., Tuzcu E.M., Sipahi I., Grasso A.W., Schoenhagen P., Hu T., Wolski K., Crowe T., Desai M.Y., Hazen S.L., Kapadia S.R., and Nissen S.E. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297 (2007) 499-508
12. Rydén L., Standl E., Bartnik M., Van Den Berghe G., Betteridge J., de Boer M.J., Cosentino F., Jönsson B., Laakso M., Malmberg K., Priori S., Ostergren J., Tuomilehto J., Thrainsdottir I., Vanhorebeek I., Stramba-Badiale M., Lindgren P., Qiao Q., Priori S.G., Blanc J.J., Budaj A., Camm J., Dean V., Deckers J., Dickstein K., Lekakis J., McGregor K., Metra M., Morais J., Osterspey A., Tamargo J., Zamorano J.L., Deckers J.W., Bertrand M., Charbonnel B., Erdmann E., Ferrannini E., Flyvbjerg A., Gohlke H., Juanatey J.R., Graham I., Monteiro P.F., Parhofer K., Pyörälä K., Raz I., Schernthaner G., Volpe M., Wood D., Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC), and European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 28 (2007) 88-136
13. Van de Werf F., Bax J., Betriu A., Blomstrom-Lundqvist C., Crea F., Falk V., Filippatos G., Fox K., Huber K., Kastrati A., Rosengren A., Steg P.G., Tubaro M., Verheugt F., Weidinger F., Weis M., ESC Committee for Practice Guidelines (CPG), Vahanian A., Camm J., De Caterina R., Dean V., Dickstein K., Filippatos G., Funck-Brentano C., Hellemans I., Kristensen S.D., McGregor K., Sechtem U., Silber S., Tendera M., Widimsky P., Zamorano J.L., Silber S., Aguirre F.V., Al-Attar N., Alegria E., Andreotti F., Benzer W., Breithardt O., Danchin N., Di Mario C., Dudek D., Gulba D., Halvorsen S., Kaufmann P., Kornowski R., Lip G.Y., and Rutten F. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 29 (2008) 2909-2945
14. Canadian Cardiovascular Society, American Academy of Family Physicians, American College of Cardiology, American Heart Association, Antman E.M., Hand M., Armstrong P.W., Bates E.R., Green L.A., Halasyamani L.K., Hochman J.S., Krumholz H.M., Lamas G.A., Mullany C.J., Pearle D.L., Sloan M.A., Smith Jr. S.C., Anbe D.T., Kushner F.G., Ornato J.P., Pearle D.L., Sloan M.A., Jacobs A.K., Adams C.D., Anderson J.L., Buller C.E., Creager M.A., Ettinger S.M., Halperin J.L., Hunt S.A., Lytle B.W., Nishimura R., Page R.L., Riegel B., Tarkington L.G., and Yancy C.W. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008 (2007) 210-247
15. Brunzell J.D., Davidson M., Furberg C.D., Goldberg R.B., Howard B.V., Stein J.H., Witztum J.L., and American Diabetes Association and the American College of Cardiology Foundation. Lipoprotein management in patients with cardiometabolic risk. Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 31 (2008) 811-822
16. Nissen S.E., Tuzcu E.M., Schoenhagen P., Crowe T., Sasiela W.J., Tsai J., Orazem J., Magorien R.D., O'Shaughnessy C., Ganz P., and Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 (2005) 29-38
17. Nissen S.E., Nicholls S.J., Sipahi I., Libby P., Raichlen J.S., Ballantyne C.M., Davignon J., Erbel R., Fruchart J.C., Tardif J.C., Schoenhagen P., Crowe T., Cain V., Wolski K., Goormastic M., Tuzcu E.M., and ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295 (2006) 1556-1565
18. Mizuno K., Nakaya N., Ohashi Y., Tajima N., Kushiro T., Teramoto T., Uchiyama S., Nakamura H., and MEGA Study Group. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the management of elevated cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). Circulation 117 (2008) 494-502
19. Okazaki S., Yokoyama T., Miyauchi K., Shimada K., Kurata T., Sato H., and Daida H. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study. Circulation 110 (2004) 1061-1068
20. Ishikawa K., Tani S., Watanabe I., Matsumoto M., Furukawa K., Nomoto K., Nomoto K., Kushiro T., Nagao K., and Kanmatsuse K. Effect of pravastatin on coronary plaque volume. Am J Cardiol 92 (2003) 975-977
21. Tani S., Watanabe I., Anazawa T., Kawamata H., Tachibana E., Furukawa K., Sato Y., Nagao K., Kanmatsuse K., Kushiro T., and Surugadai Atherosclerosis Regression Investigators. Effect of pravastatin on malondialdehyde-modified low-density lipoprotein levels and coronary plaque regression as determined by three-dimensional intravascular ultrasound. Am J Cardiol 96 (2005) 1089-1094
22. Tani S., Nagao K., Anazawa T., Kawamata H., Furuya S., Takahashi H., Iida K., Matsumoto M., Washio T., Kamabe N., and Hirayama A. Association of leukocyte subtype counts with coronary atherosclerotic regression following pravastatin treatment. Am J Cardiol 104 (2009) 464-469
23. Takayama T., Hiro T., Yamagishi M., Daida H., Saito S., Yamaguchi T., and Matsuzaki M. Rationale and design for a study using intravascular ultrasound to evaluate effects of Rosuvastatin on coronary artery atheroma in Japanese subjects: COSMOS study (Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects). Circ J 71 (2007) 271-275
24. Hiro T., Kimura T., Morimoto T., Miyauchi K., Nakagawa Y., Yamagishi M., Ozaki Y., Kimura K., Saito S., Yamaguchi T., Daida H., Matsuzaki M., and JAPAN-ACS Investigators. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using paravasation versus atorvastatin (JAPAN-ACS [Japan assessment of paravasation and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 54 (2009) 293-302